SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pfizer Ltd (PFIZER)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 500680 NSE: PFIZER Pharmaceuticals & Drugs | Small Cap | Pfizer Share Price

₹4,728.55 128.05 (2.78%)

As on 10-Jul'26 16:59

Pfizer Ltd (PFIZER)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 500680 NSE: PFIZER Pharmaceuticals & Drugs | Small Cap | Pfizer Share Price

₹4,728.55 128.05 (2.78%)

As on 10-Jul'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹21,632 Cr.
Current Price
₹4,728.6
52-Week Low / High
₹4,361 / 5,879
TTM EPS
₹157.9
TTM Sales
₹2,520 Cr.
Book Value per Share
₹918.7
P/E Ratio
29.94
Lower than its 5-year historical median
Industry PE
50
Price to Book (P/B)
5.15
Lower than its 5-year historical median
Price to Sales (P/S)
8.59
In line with its 5-year historical median
EV/EBITDA
16.96
Lower than its 5-year historical median
Dividend Yield
1.59%
Profitability Efficiency
Return on Equity (ROE)
17.16%
Outperforms industry median
Return on Capital Employed (ROCE)
23.39%
Outperforms industry median
Return on Assets (ROA)
14.91%
Operating Profit Margin
35.9%
Net Profit Margin
28.67%
Gross Profit Margin
41.2%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
10.45%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
22.13%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
-5.88%
Asset Quality
Promoter Holding
63.92%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹4,157 Cr.
Equity
₹45.8 Cr.
Face Value
₹10
All Time Low / High
₹27.50 / 6452.85

Pfizer stock performance

Key Ratios
mw4me loader

Check Before You Invest

Valuation

Somewhat Overvalued

Price Trend

Semi Strong
Q.1 Is Pfizer Ltd a good quality company?
Pfizer Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Pfizer Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Pfizer Ltd vs industry peers?
Pfizer Ltd revenue CAGR is 1.18%, compared to the industry median CAGR of 5.35%, indicating slower growth and losing its market share.
Q.1 Promoter shareholding and pledge status of Pfizer Ltd?
Promoters hold 63.92% of the Pfizer Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Pfizer Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 10.2% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Pfizer Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
ROCE % 22.6%21.5%23.2%20.4%23.6%29.8%27.6%22.4%26.2%23.4%-
Value Creation
Index
0.70.60.70.51.11.71.01.00.91.1-

Growth Parameters

Sales 1,9661,9692,0822,1522,2392,6112,4252,1932,2812,5202,520
Sales YoY Gr.-0.1%5.7%3.4%4%16.6%-7.1%-9.6%4%10.5%-
Adj EPS 52.977.789.4106.8108133.4131119.8141.6165.4157.9
YoY Gr.-46.9%15.1%19.5%1.1%23.5%-1.8%-8.5%18.2%16.8%-
BVPS (₹) 528.7586.5658.2742.2523.1626.1701.1785.9921.8918.7918.7
Adj Net
Profit
242355409489494610599548648756722
Cash Flow from Ops. 32933297.8323427667356257660968-
Debt/CF from Ops. 0000000000-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales 2.8%2.4%1.3%10.5%
Adj EPS 13.5%8.9%8.1%16.8%
BVPS6.3%11.9%9.4%-0.3%
Share Price 9.4% -3.7% 7.6% -14.1%

Key Financial Parameters

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
Return on
Equity %
10.613.914.415.317.123.219.716.116.61817.2
Op. Profit
Mgn %
17.825.527.326.931.832.133.429.232.535.935.9
Net Profit
Mgn %
12.318.119.722.722.123.424.72528.43028.7
Debt to
Equity
00000000000
Working Cap
Days
150162182195194169182208206163258
Cash Conv.
Cycle
-10-40-27-462023455749213

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Sales1,9661,9692,0822,1522,2392,6112,4252,1932,2812,520
Operating Expenses + 1,6161,4681,5161,5791,5261,7751,6161,5581,5411,615
Manufacturing Costs162131143116130138129118109118
Material Costs712678678742734876803730756828
Employee Cost 304314324365361404332348371368
Other Costs 439345370357301358352362305302
Operating Profit 350501566573712836809635740904
Operating Profit Margin (%) 17.8%25.4%27.2%26.6%31.8%32.0%33.4%29.0%32.5%35.9%
Other Income + 1011141671848163101181172188
Exceptional Items 13000000338173-49
Interest 2121115111315910
Depreciation 636671103109115106626158
Profit Before Tax 5175486606426697738247461,016976
Tax 180188231133171160200195248253
Profit After Tax 337360429509498613624551768722
PAT Margin (%) 17.1%18.3%20.6%23.7%22.2%23.5%25.7%25.1%33.7%28.7%
Adjusted EPS (₹)73.678.793.8111.3108.8133.9136.4120.5167.8157.9
Dividend Payout Ratio (%)27.20%25.40%24%296.50%32.20%22.40%51.30%29%98.30%47.50%

Valuation of Pfizer - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + 2,4192,6833,0113,3952,3932,8643,2073,5964,2174,203
Share Capital 46464646464646464646
Reserves 2,3732,6372,9663,3502,3472,8193,1623,5504,1724,157
Debt +3333333333
Long Term Debt0000000000
Short Term Debt3333333333
Minority Interest0000000000
Trade Payables388496436427284264217166152216
Others Liabilities 452509490580573723476411470428
Total Liabilities 3,2613,6903,9404,4053,2523,8543,9034,1754,8424,850

Fixed Assets

Net Fixed Assets +867917854942865841749713724678
Gross Block9831,0951,1001,2771,2791,3451,3521,3561,4181,418
Accumulated Depreciation116178246335414504603643695740
CWIP 151013180820
Investments 0000000000
Inventories322297387431435449418434476473
Trade Receivables110155172172109143152188193182
Cash Equivalents flag 1,5231,7721,9142,2201,1151,6431,8602,0472,8013,111
Others Assets 423549613640726777717794641386
Total Assets 3,2613,6903,9404,4053,2523,8543,9034,1754,8424,850

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Cash Flow From Operating Activity + 32933298323427667356257660968
PBT 5175486606426697738247461,016976
Adjustment -154-33-79-545576-131-89-246-63
Changes in Working Capital 14910-245-52-9244-34-2464540
Tax Paid -183-194-238-213-204-226-303-154-15615
Cash Flow From Investing Activity + -250-238351,530-469-575-3654-71-562
Capex 169-6927-2-18-13-6434-28-24
Net Investments -502000-502-613-229-109-354-715
Others 84-16981,5325151257129311177
Cash Flow From Financing Activity + -83-110-110-164-1,571-181-346-235-205-798
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid 000-0-3-11-13-11-8-9
Dividend Paid -69-92-91-103-1,519-160-297-183-160-752
Others -14-19-19-60-49-10-35-41-37-38
Net Cash Flow -3-17231,690-1,613-88-2675383-392

Financial Ratio

PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Ratios
ROE (%)14.714.1115.0715.8917.1923.320.5516.2119.6517.16
ROCE (%)22.6221.4923.2220.3823.6229.7827.5622.3726.2123.39
Asset Turnover Ratio0.660.570.550.520.580.760.660.570.530.54
PAT to CFO Conversion(x)0.980.920.230.630.861.090.570.470.861.34
Working Capital Days
Receivable Days22.6024.4028.6029.2022.9016.902126.7029.1026.10
Inventory Days6157.106069.3070.6059.4061.8067.1069.5066
Payable Days186.20238250.60212.30176.60114.20109.4095.9076.8081

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Pfizer Ltd FAQs

The current trading price of Pfizer on 10-Jul-2026 16:59 is ₹4,728.6.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 09-Jul-2026 the market cap of Pfizer stood at ₹21,632 Cr

The latest P/E ratio of Pfizer as of 09-Jul-2026 is 29.94.

The latest P/B ratio of Pfizer as of 09-Jul-2026 is 5.15.

The 52-week high of Pfizer is ₹5,878.6 and the 52-week low is ₹4,361.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Pfizer is ₹2,520 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Pfizer Ltd is a good quality company.

The key valuation ratios of Pfizer Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Pfizer Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Pfizer Ltd

Pfizer is one of the world’s leading pharmaceutical companies and began its operations in India in 1950. The company is specialised with expert therapy in four business categories - Vaccines, Hospitals, Internal Medicine and Inflammation and Immunology. The company applies cutting-edge science and its global resources to bring therapies to people that extend and significantly improve their lives. The company strives to set the standard for quality, safety and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. 

The company continuously works across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of its time. Consistent with its responsibility as one of the world's premier innovative biopharmaceutical companies, the company collaborates with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. 

Business area of the company

Pfizer is engaged in manufacturing, marketing, distribution and trading of pharmaceutical products. The company has its own manufacturing facility. The company also has various independent contract / third party manufacturers based across the country. The company sells its products primarily in India through independent distributors.

Key products

  • Vaccines
  • Anti-infectives
  • Internal Medicine 
  • Inflammation and Immunology

Awards

2001

  • OPPI Brand Excellence Award for Minipress XL.

2002

  • Express Pharma Biz Award for overall performance.
  • Rated as one of India's most socially responsive companies. Awarded by FICCI-Socio Economic Development Foundation for Social Responsiveness.

2003

  • Voted as the 5 'Most Respected Company' in the Pharma sector (Business World).
  • Corporate Advertising Campaign won a Silver Award at the ABBY-All India Awards for Creative Excellence. Gelusil brand received a Silver Award for printing advertising.
  • Golden Peacock National Training Special Commendation for Training practices.

2004

  • Ranked 5 among all pharmaceutical companies, with respect to corporate image, field-force, and promotional programs (AC Nielsen-ORG Marg 'Corporate Image Survey').
  • Ranked 1 among all Pharma MNCs & 4 among all Pharma Companies by Business World.
  • Kewal Handa, CFO Pfizer receives the ‘India CFO 2004 - Excellence in Finance in an MNC’ by International Market - Assessment Group.

2005

  • Golden Peacock Innovative Service Award for Prime MD Today (Daxid).
  • PC Quest 'Best IT Implementation Users Choice' award for OPTILEARN.
  • Pharma Excellence Awards 2006 in 'Innovative Products of the Year' category for Exubera.
  • Ranked 1 among multinationals and #3 among all pharmaceuticals, in the Business World survey.

2006

  • Pharma Excellence Awards 2006 in 'Innovative Products of the Year' category for Exubera.
  • Ranked 1 among multinationals and 3 among all pharmaceuticals, in the Business World survey.
  • Kewal Handa, Managing Director Pfizer, awarded the Bharat Shiromani award for his outstanding contribution in the pharmaceutical industry.

2007

  • Reader’s Digest Trusted Brand Asia - Gold Award 2007’ in the vitamin and health supplement category for Becosules.

2008

  • Frost & Sullivan Brand Strategy Leadership Award for Becosules in the Indian Dietary Supplement Market.
  • Pfizer India was recently conferred the ‘Innovative Training Practices’ Award for promoting effective and optimum utilization of human resource through education and training by the Indian Society for Training and Development (ISTD).

2009

  • Pfizer (India) conferred the Multinational Pharmaceutical Company of the Year by Frost & Sullivan.

2010

  • Pfizer awarded the Most Admired Pharmaceutical Company of the Year by Pharma Leaders Magazine.
  • Kewal Handa, Country Manager - Pfizer recognized as Pharma Professional of the Year by Pharma Leaders Magazine.
  • Pfizer wins the Community Engagement Award at the Asia Responsible Entrepreneurship Awards 2010 in India.

2011

  • Pfizer India has been recognized as one of The Best Companies to Work For by Business Today magazine.

2012

  • J.D. Power and Associates has honored the MS LifeLines call center with certification for an outstanding customer service experience. This is the first time J.D. Power has recognized a pharmaceutical call center. 

2013

  • GBCHealth Business Leadership Award - in recognition for the Global Health Fellows program. This award is given annually to a company or business leader with a deep and long-term commitment to global health that extends beyond the business objective of the company itself. Caroline Roan will be accepting the award on behalf of Pfizer.
  • Business Action on Health Award in Application of Core Competence for Global Health Fellows Program (commendation). Oonagh Puglisi will be accepting the award for the GHF program.
  • Business Action on Health Award in Partnership/Collective Action for Advancing Cancer & Tobacco Control in China Program. Danlong Feng, Corporate Affairs Director, Pfe China, will be accepting the award.
  • QUESTAR Award - The International Awards Festival for Excellence in Video Communications Pfizer was awarded the Grand -- best of category -- in Annual Reports in the 2013 Questar Awards.
  • Telly Award - For over a quarter century, the Telly statuette has been a symbol of creative excellence. Pfizer was awarded - Bronze at the 2013 Telly's for online videos.

2017

  • The company was awarded the ‘Swachhta Pharma Award’ by Union Minister, Ananth Kumar, and Union Minister of State, Mansukh Mandaviya, from the Ministry of Chemicals & Fertilizers at the flagship India Pharma 2017 conference.
2022

  • Winner of ‘ICAI Award for Excellence in Financial Reporting 2021-22’ in the Silver Shield category by The Institute of Chartered Accountants of India under the Manufacturing and Trading category.
2023

  • The company was honoured with the 2023 Pfizer Global Service Performance Award for the extraordinary efforts in making the site an amazing workplace for all.
2024

  • The company received the 2024 Pfizer Global Service Performance Team Award for exceptional progress in enhancing capacity utilisation and fostering a highquality work environment at the site.

Milestones:

  • 1849: Charles Pfizer & Company established. 1' product for treatment of intestinal worms is a success.
  • 1880: Pfizer manufactures Citric Acid. Rapid growth on the back of aerated drinks demand.
  • 1882: Alexander Fleming discovers penicillin.
  • 1944: Pfizer finds a way to mass-produce Penicillin.
  • 1950: Terramycin, the 1st pharmaceutical sold in the US under the Pfizer label.
  • 1950: India operation launched, with HQ in Mumbai.
  • 1966: Pfizer listed on the Bombay Stock Exchange.
  • 1989: Dolonex (Feldene) launched in India.
  • 1993: Amlogard (Norvasc) launched in India.
  • 1996: Launch of MinipressXL, an anti hypertensive drug.
  • 1998: Launch of Viagra, for erectile dysfunction.
  • 1999: Pfizer listed on the National Stock Exchange.
  • 2000: Launch of Magna& a unique hospital antibiotic.
  • 2002: Futuristic tablet manufacturing Goa plant commissioned in a record 13 months.
  • 2003 Completes merger with Parke-Davis (India) Ltd.
  • 2005: Announces merger with Pharmacia Healthcare ltd.
  • 2006: Launch of LYRICA (pregaballn for treatment of neuropathic pain)
  • 2008: Launch of Champix - a non-nicotine smoking cessation prescription drug.
  • 2010: Launch of Prevenar 13, vaccine for prevention of pneumococcal disease and included later in India’s Universal Immunization Programe.
  • 2015: Completed merger with Wyeth.
  • 2016: Launched Xeljanz-the first oral Janus Kinase (JAK) inhibitor.
  • 2017: Acquires 2 breakthrough brands- Meronem, Neksium.
  • 2019: Reorganizes into 3 distinct business units: Pfizer Biopharma Group, UpJohn and Consumer Healthcare. New purpose and values unveiled.
  • 2019: Launches novel anti-bacterial Zavicefta in India.
  • 2020: Launch of Zinforo, a noval cephalosporin indicated for treatment of adult patients with community- acquired Pneumonia.
  • 2021: Pfizer Inc. donated COVID-19 treatment drugs worth $70 million to India, while the Company contributed Magnex valued at around Rs 12 crore, supporting the country’s pandemic response efforts.
  • 2024: Pfizer joined hands with NIPER (Ahmedabad) to support Healthcare Innovation in India.
  • 2025: Pfizer launched its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India.
  • 2025: Pfizer has introduced Rimegepant ODT in India for adults with a previous insufficient response to triptan, the usual drugs for treating migraine.
You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: